Recombinant Human LILRB3/CD85a/ILT5 Protein, CF

When Recombinant Human LILRB3/CD85a/ILT5 (Catalog # 9159-T5) is coated onto a microplate at 2 µg/mL, Recombinant Human Angiopoietin-like 7 (Catalog # 914-AN) binds with an ED50 of 50-300 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LILRB3/CD85a/ILT5 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LILRB3/CD85a/ILT5 is coated at 2 μg/mL, Recombinant Human Angiopoietin-like 7 (Catalog # 914-AN) binds with an ED₅₀ = 50-300 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human LILRB3/CD85a/ILT5 protein
  Gly24-Glu443, with a C-terminal 6-His tag
• Accession #: AAB68668
• N-terminal Sequence: Gly24
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 47 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-69 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LILRB3/CD85a/ILT5 Protein, CF

• CD85 antigen-like family member A
• CD85a antigen
• CD85a
• HL9Immunoglobulin-like transcript 5
• ILT5
• ILT-5
• ILT5CD85a
• Leukocyte immunoglobulin-like receptor 3
• leukocyte immunoglobulin-like receptor subfamily B member 3
• leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains)
• LILRB3
• LIR3
• LIR3CD85A
• LIR-3MGC138403
• member 3
• Monocyte inhibitory receptor HL9
• PIRB

Background

Leukocyte immunoglobulin-like receptor subfamily B (LILRB3), also known as ILT5, LIR3, and CD85a, is an immunoglobulin superfamily member that is involved in immune regulation. Subfamily B members have cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events via phosphatase SHP-1. Subfamily A members are activating receptors that lack ITIMs and signal through association with FcR gamma (1, 2). Mature LILRB3 is a highly polymorphic 85-95 kDa glycoprotein that consists of a 420 amino acid (aa) extracellular domain (ECD) with four Ig-like domains, a 21 aa transmembrane segment, and a 167 aa cytoplasmic domain with three ITIMs (3). Alternative splicing generates an isoform with a 17 aa insertion in the juxtamembrane ECD. In mouse and rat, the LILRB3 gene encodes the PIR-B protein which has six Ig-like domains. Rodent PIR-B and human LILRB3 share 55% aa sequence identity within common regions of their ECDs. LILRB3 is expressed on the surface of peripheral monocytes, neutrophils, eosinophils, basophils, and mast cell progenitors (4-6). Triggering of LILRB3 inhibits the activation of macrophages, mast cells, neutrophils, basophils, and B cells (5, 7). On osteoclast precursors, LILRB3 ligation inhibits RANK L/TRANCE or M-CSF induced differentiation (8). LILRB3 can also bind to ligands exposed on necrotic tumor cells (9). Both PIR-B and LILRB3 are receptors for S. aureus, and activation of these receptors by bacteria influences the innate immune response triggered by TLRs (3). R&D Systems in-house testing indicates that LILRB3 binds to
Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (10). In the mouse CNS, PIR-B functions as a receptor for the myelin proteins Nogo, MAG, and OMgp and mediates their inhibitory action on neurite outgrowth and axon regeneration (11). Upon binding to MAG, PIR-B associates with TrkB and NGF R/p75 in cerebellar granule neurons (12).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Anderson, K.J. and R.L. Allen (2009) Immunology 127:8.
3. Nakayama, M. et al. (2007) J. Immunol. 178:4250.
4. Tedla, N. et al. (2003) Proc. Natl. Acad. Sci. USA 100:1174.
5. Sloane, D.E. et al. (2004) Blood 104:2832.
6. Tedla, N. et al. (2008) J. Leukoc. Biol. 83:334.
7. Uehara, T. et al. (2001) J. Clin. Invest. 108:1041.
8. Mori, Y. et al. (2008) J. Immunol. 181:4742.
9. Jones, D.C. et al. (2016) Oncotarget PMID 26769854.
10. Zheng, J. et al. (2012) Nature 485:656.
11. Atwal, J.K. et al. (2008) Science 322:967.
12. Fujita, Y. et al. (2011) Cell Death Dis. 2:e198.

Publications for ILT5/CD85a/LILRB3 (9159-T5)(1)

Publication using 9159-T5

• Martinez-Martin N, Marcandalli J, Huang C, Arthur C, Perotti M, Foglierini M, Ho H, Dosey A, Shriver S, Payandeh J, Leitner A, Lanzavecchia A, Perez L, Ciferri C An Unbiased Screen for Human Cytomegalovirus Identifies Neuropilin-2 as a Central Viral Receptor. Cell, 2018-07-26;174(5):1158-1171.e19. 2018-07-26 [PMID: 30057110] (Biolayer Interferometry (BLI), Virus)

Bioinformatics

• Uniprot:
  • AAB68668()